Despite Health Insurance, Illinois Woman's Cancer Diagnosis Leads To Bankruptcy +... +...

Despite Health Insurance, Illinois Woman's Cancer Diagnosis Leads To Bankruptcy Angie Salvador made too much to qualify for Medicaid but too little to afford the high costs of healthcare, the St. Louis Post-Dispatch reports. Following her breast cancer diagnosis and $8,400 in new medical debt, she filed for bankruptcy. "I'm assuming that you can get excellent quality healthcare in the United States," Salvador said. "I just don't know anybody that's able to afford it." https://kffhealthnews.org/morning-breakout/cancer-061626/ Viewpoints: Insurers' Flawed System For Denials Puts Patients In Danger; Congress Must Stop Tiptoeing Around Impending Medicare, Social Security Crises https://kffhealthnews.org/morning-breakout/viewpoints-insurers-flawed-system-for-denials-puts-patients-in-danger-congress-must-stop-tiptoeing-around-impending-medicare-social-security-crises/

Independent Doctors Decry Shift To Private-Equity Firm, But Aren't Sure What To Do Next

Independent Doctors Decry Shift To Private-Equity Firm, But Aren't Sure What To Do Next Valley Health hospitals in Virginia announced plans to end a contract with emergency medicine physicians and partner with a private equity-owned practice management company, blindsiding staff. Physicians who agreed to stay on under new contracts would no longer qualify for health insurance or retirement benefits, MedPage Today reports. https://kffhealthnews.org/morning-breakout/health-industry-061626/

Colorado Cleared To Import Lower-Cost Drugs From Canada

Colorado Cleared To Import Lower-Cost Drugs From Canada The Centennial State is the second to gain FDA approval of a program to bring down prescription drug costs for its residents. Florida earned the approval in 2024, but it has yet to begin importing any drugs, Stat reports. https://kffhealthnews.org/morning-breakout/state-watch-9/

FDA Approves Medical-Grade Maggots For Debridement Therapy

FDA Approves Medical-Grade Maggots For Debridement Therapy The biomedical developer Cuprina Holdings thinks this is the first debridement product to use this particular species, dubbed Medifly Maggots. Maggot debridement therapy has been associated with a lower risk of lower-limb amputation in diabetics with non-healing lesions, MedPage Today reports. https://kffhealthnews.org/morning-breakout/science-and-innovations-061626/

RFK Jr. Directs Woman To Remain In Hantavirus Quarantine Unit Weeks After Others Went Home

RFK Jr. Directs Woman To Remain In Hantavirus Quarantine Unit Weeks After Others Went Home The New York Times reports that Health Secretary Robert F. Kennedy Jr. signed an order to continue holding Angela Perryman at a quarantine facility in Nebraska, against her wishes and despite a CDC recommendation Thursday that she be allowed to return home for the remainder of her 42-day quarantine. https://kffhealthnews.org/morning-breakout/outbreaks-and-health-threats-061626/

Trump Admin Requests Expedited Appeal Of Ruling Blocking HHS Vaccine Policies

Trump Admin Requests Expedited Appeal Of Ruling Blocking HHS Vaccine Policies A federal court ruled in March to temporarily block a number of vaccine decisions made by Health Secretary Robert F. Kennedy Jr. while a lawsuit brought by six medical organizations continued. The ruling froze all decisions made by the Advisory Committee for Immunization Practices and prevented its advisers from meeting as scheduled, The New York Times reports. https://kffhealthnews.org/morning-breakout/administration-news-061626/

Development of Antihypertensive Therapies for Use in Pediatric Patients July 15 - 16, 2026

https://www.fda.gov/drugs/news-events-human-drugs/development-antihypertensive-therapies-use-pediatric-patients-07152026?utm_medium=email&utm_source=govdelivery FDA Workshop Will Focus on Development of Antihypertensive Therapies for Use in Pediatric Patients Treatment of chronic hypertension (high blood pressure) in pediatric patients remains an area of unmet medical need, with limited FDA-approved therapies, particularly for children younger than six years of age. Products are being developed to treat uncontrolled and/or resistant hypertension in adults that may have benefits in pediatric patients. This FDA public workshop, hosted with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), will bring together key stakeholders, including clinicians, academicians, regulators, industry, and patients/caregivers, to discuss the similarities and differences in disease pathophysiology and drug response across age groups, determine the extent to which efficacy can be extrapolated from adults to pediatrics, identify development priorities for both initial therapy and uncontrolled hypertension, and explore feasible strategies to generate evidence for the safe and effective use of antihypertensive treatment(s) in pediatric patients with hypertension, including children younger than six years of age. Please visit this webpage for more information and to register for the meeting.